Study of BMS-986158 in Subjects With Select Advanced Cancers

• Status: Active, not recruiting
• Trial end date: 2021-08-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Nivolumab

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Must have select advanced cancers with specific genetic profiles

• Must have received appropriate standard of care

• At least one measurable lesion at baseline

• Expected to have life expectancy of at least 3 months

• Eastern Cooperative Oncology Group (ECOG) of 0 to 1

Exclusion Criteria:

• Concomitant second malignancies

• Uncontrolled or significant cardiovascular disease

• Inadequate bone marrow function

• Chronic gastrointestinal illness

• Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor

Other protocol defined inclusion/exclusion criteria could apply